The Mainz-based vaccine manufacturer BioNTech expects sales to fall significantly in the 2024 financial year due to shrinking sales of the Covid-19 vaccine.
The company announced on Tuesday at the JP Healthcare Conference industry meeting in San Francisco, USA, that revenues totaling around three billion euros are expected. The Mainz company recently expected sales of around four billion euros for 2023. BioNTech plans to present the figures for last year on March 20, along with a detailed financial forecast for 2024.
The focus this year will be on the further development of cancer therapies with a whole series of studies. According to its own information on Tuesday, BioNTech expects sales growth again in 2025. In the years thereafter – subject to approval – income from the market launch of combined vaccines and products for cancer therapies is expected.
The BioNTech share was temporarily down 2.06 percent at $109.57 in pre-market trading on NASDAQ.
/chs/DP/jha
MAINZ (dpa-AFX)
Selected leverage products on BioNTech (ADRs)
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on BioNTech (ADRs)
The leverage must be between 2 and 20
Advertising
Image sources: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images, Thomas Lohnes/Getty Images